Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case–control study
Open Access
- 12 August 2022
- journal article
- research article
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 23 (1) , 1-10
Abstract
Background: The burden of post-coronavirus disease (COVID)-19 symptoms has been increasing and is of great concern in patients with pre-existing chronic medical conditions.This study aimed to delineate the post-COVID-19 neuropsychiatric symptoms among migraine patients compared to the non-migraine control group. Methods: Two groups, each of 204 COVID-19 survivors, were enrolled in the study after 3 months of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, one group fulfilling the episodic migraine criteria and the other serving as a matching control group. Subjects were evaluated through an in-person interview for post-COVID-19 neuropsychiatric symptoms, including detailed headache patterns and severity, using the visual analogue scale. Results: The Frequency of headache during the acute phase of COVID-19 was more frequent in migraine patients (OR = 1.60, 95%CI = 1.04–2.45, P-value = 0.031). The reported significant post-COVID-19 neuropsychiatric symptoms in migraine patients compared to controls were fatigue (OR = 1.662, 95%CI = 1.064–2.596, P-value = 0.025), anosmia/hyposmia (OR = 2.06, 95%CI = 1.164- 3.645, P-value = 0.012), cacosmia (OR = 2.663, 95%CI = 1.145–6.195, P-value = 0.019), depression (OR = 2.259, 95%CI = 1.284- 3.975, P-value = 0.004), anxiety (OR = 3.267, 95%CI = 1.747- 6.108, P-value ≤ 0.001), insomnia (OR = 2.203, 95%CI = 1.298- 3.739, P-value = 0.003), and headache (OR = 3.148, 95%CI = 1.616–6.136, P-value = ≤ 0.001).While there was no statistically significant difference between migraine patients and controls regarding the post-COVID-19 functional status score (P-value = 0.102). The pattern of post-COVID-19 headache was reported as chronic headache transformation in 17.6% of the migraine group, with the median intensity rate being 5.5 and IQR (3–7). In the control group, 14% experienced chronic headache attributed to systemic viral infection with a median intensity rate of 2 and IQR (2–5), while 12% experienced a new daily persistent headache with a median intensity of 5 and IQR (1–6). Conclusion: The study highlighted the importance of follow-up migraine patients upon recovery from COVID-19 infection, being more vulnerable to post-COVID-19 symptoms.Keywords
This publication has 48 references indexed in Scilit:
- Serotonergic mechanisms in the migraine brain – a systematic reviewCephalalgia, 2016
- Beyond Myalgic Encephalomyelitis/Chronic Fatigue SyndromeJAMA, 2015
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studiesInternational Journal of Surgery, 2014
- The International Classification of Headache Disorders, 3rd edition (beta version)Cephalalgia, 2013
- Defining the Differences Between Episodic Migraine and Chronic MigraineCurrent Pain and Headache Reports, 2011
- Psychiatric comorbidity and suicide risk in patients with chronic migraineNeuropsychiatric Disease and Treatment, 2010
- Relationship between insomnia and headache in community-based middle-aged Hong Kong Chinese womenThe Journal of Headache and Pain, 2010
- Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferersJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Fatigue in Chronic Migraine PatientsCephalalgia, 2002
- Hypothalamic involvement in chronic migraineJournal of Neurology, Neurosurgery & Psychiatry, 2001